Compare Lockheed Martin Corporation (LMT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lockheed Martin Corporation vs GeneDx Holdings Corp — how do they compare? Lockheed Martin Corporation trades at $597.7 (market cap $137.96B), while GeneDx Holdings Corp trades at $82.64 (market cap $2.44B). The key difference: Lockheed Martin Corporation is far larger — about 56.5× GeneDx Holdings Corp's market cap, and Lockheed Martin Corporation pays a 2.31% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| LMT | WGS | |
|---|---|---|
Market Cap | $137.96B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $676.70 | $167.51 |
52-Week Low | $431.56 | $34.51 |
Enterprise Value | $154.71B | $2.48B |
Dividend Yield | 2.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lockheed Martin (LMT) trades at $603.16, up 2.59% with strong technical momentum and bullish moving averages. The company reported mixed Q2 2026 earnings with a beat on EPS but faces margin pressure with net income margin declining to 8.16%. Recent news highlights major defense contracts including a $53.9 billion Patriot missile order and successful testing of next-generation interceptors, supporting the record $230 billion backlog.
Outlook remains positive with analyst consensus at Buy (56.76%) and $608 price target, though risks include execution on massive backlog and margin sustainability. The stock offers steady dividends ($3.45 quarterly) and benefits from elevated defense spending, but valuation multiples (P/E 22.04) require continued earnings growth to justify upside.
GeneDx Holdings Corp (WGS) trades at $82.36, up 5.75% in 24 hours, with a bullish technical signal and strong analyst support. Recent Q2 2026 results beat expectations with $0.01 EPS and record testing volumes, though net income margins remain negative. The stock faces class action litigation risks but benefits from institutional buying and new product launches.
Outlook is mixed: bullish technicals and 91% buy ratings suggest upside to the $90 high target, but negative profitability and legal overhangs pose risks. Investors should weigh growth potential against financial sustainability and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
